Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
This multicenter IMWG study identifies relapsed multiple myeloma patients who:
- have received at least three prior lines of therapy,
- are refractory to both an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI), and
- have been exposed to an alkylating agent.
Learn more about how this study sheds light on the expected outcome of relapsed myeloma patients that are refractory to a PI and an IMiD, which is a benchmark for comparing new therapies.
Shaji Kumar, Meletios A Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, Jens Hillengass, Xavier Leleu, Meral Beksac, Melissa Alsina, Albert Oriol, Michele Cavo, Enrique M. Ocio, Maria Victoria Mateos, Elizabeth K. O’Donnell, Ravi Vij, Henk M. Lokhorst, Niels W.C.J. van de Donk, Chang-Ki Min, Tomer Mark, Ingemar Turesson, Markus Hansson, Heinz Ludwig, Sundar Jagannath, Michel Delforge, Charalampia Kyriakou, Parameswaran Hari, Ulf-Henrik Mellqvist, Saad Z Usmani, Dominik Dytfeld, Ashraf Z Badros, Philippe Moreau, Kihyun Kim, Paula Rodriguez Otero, Jae Hoon Lee, Chaim Shustik, Daniel Waller, Wee Joo Chng, Shuji Ozaki, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, Laura Rosinol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim and Brian G.M. Durie
click here to view article: